rs201457110 — DCHS1

DCHS1 R2513H — A Valve-Shaping Gene Variant Linked to Mitral Valve Prolapse

Mitral valve prolapse (MVP) affects approximately 1 in 40 people globally, making it the most common heart valve abnormality — yet for decades its molecular causes were largely unknown. DCHS1 (Dachsous Cadherin-Related 1) encodes a protocadherin that functions as an intercellular signal in the planar cell polarity (PCP) pathway¹¹ planar cell polarity (PCP) pathway
A signaling system that coordinates the orientation and movement of cells within a tissue plane during organ development, and its product is essential for the proper morphogenesis of heart valves. The rs201457110 variant introduces an arginine-to-histidine change at position 2513 of the DCHS1 protein, destabilizing the protein and disrupting the cellular architecture of the developing mitral valve.

This is a rare pathogenic variant — the T allele is carried by roughly 1 in 4,000 people globally, though the frequency is considerably higher in East Asian populations (~1 in 300). The variant is autosomal dominant: a single copy of the T allele is sufficient to cause valve disease in affected family members.

The Mechanism

DCHS1 operates as part of the DCHS1–FAT4 signaling axis²² DCHS1–FAT4 signaling axis
FAT4 is the binding partner of DCHS1; together they transmit planar polarity signals from cell to cell during organogenesis, controlling how cells orient themselves and migrate during organ formation. In the developing heart, this pathway is required for normal mitral leaflet morphogenesis — shaping the thin, pliable leaflets that prevent blood from flowing backward from the left ventricle into the atrium during each heartbeat.

The R2513H variant does not impair mRNA production; instead, it dramatically accelerates protein degradation. In transfected cell models, the mutant DCHS1 protein was reduced by approximately 60% compared to wild-type, with the protein's half-life falling from 5.8 hours to just 1.6 hours — the hallmark of a loss-of-function destabilization mechanism³³ loss-of-function destabilization mechanism
The protein is made normally but is degraded too rapidly, so less of it is available for intercellular signaling. This reduced DCHS1 dosage impairs the coordinated cell migration and polarity signals that sculpt the mitral leaflets during fetal development, leading to myxomatous thickening and elongation of the leaflets that physically prolapse into the left atrium during systole.

The Evidence

The variant was first identified by Durst et al. (Nature, 2015)⁴⁴ Durst et al. (Nature, 2015)
50-author multi-center collaboration; identified DCHS1 mutations in three families with familial MVP through linkage analysis and exome sequencing of a five-generation family. The R2513H mutation co-segregated with MVP in all tested family members, was absent from 4,300 European-American controls in the NHLBI Exome Sequencing Project, and failed to rescue zebrafish atrioventricular canal defects that wild-type DCHS1 mRNA fully corrected — establishing pathogenicity beyond segregation alone. A parallel mouse model (Dchs1+/− heterozygous knockouts) spontaneously developed mitral valve prolapse with a characteristically elongated posterior leaflet, directly mirroring the human disease phenotype.

The broader clinical significance of DCHS1 variants was extended by Clemenceau et al. (2018)⁵⁵ Clemenceau et al. (2018)
Sequencing all 21 DCHS1 exons in 100 unrelated patients with moderate-to-severe mitral regurgitation, who found that 24 out of 100 sporadic MVP cases carried at least one predicted-deleterious DCHS1 missense variant, suggesting DCHS1 accounts for a substantial fraction of apparently sporadic MVP. A minority of studies in primarily sporadic cohorts have found lower rates, underscoring that DCHS1 is one of several MVP genes rather than a singular universal cause.

The variant is classified as Pathogenic in ClinVar (VCV000217870) for the condition "Mitral valve prolapse, myxomatous 2" (OMIM 607829), based on the family segregation and functional evidence.

Practical Actions

MVP caused by DCHS1 mutations ranges from clinically silent leaflet thickening to hemodynamically significant mitral regurgitation requiring surgical repair. Importantly, a subset of MVP patients — particularly those with bileaflet involvement, mitral annular disjunction, or complex ventricular ectopy — faces elevated risk of ventricular arrhythmia and sudden cardiac death⁶⁶ ventricular arrhythmia and sudden cardiac death
Studies of arrhythmogenic MVP identify papillary muscle fibrosis and myocardial stretch as the substrate for life-threatening arrhythmias in susceptible individuals.

For T allele carriers, the priority is cardiology evaluation to establish baseline mitral valve anatomy and function. Echocardiography is the definitive diagnostic and surveillance tool. Asymptomatic individuals with minimal or no mitral regurgitation on baseline echo can typically be followed every 3–5 years; those with significant regurgitation or high-risk features (bileaflet prolapse, biphasic T waves in inferior leads, frequent premature ventricular contractions) require closer monitoring including 24-hour Holter recording. First-degree relatives of affected individuals should also be offered echocardiographic screening.

Interactions

DCHS1 functions as the ligand for FAT4 in the planar cell polarity pathway. Other genes in the MVP genetic architecture include FLNA (X-linked filamin A, causing X-linked MVP), DZIP1, and PLD1. DCHS1 mutations act in isolation as an autosomal dominant monogenic cause of MVP; no specific gene-gene interactions at the variant level have been characterized, but the shared DCHS1–FAT4 signaling axis means that FAT4 variants may theoretically modify expressivity.